Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective (Q26830864)

title

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective (English)

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

William Rawlinson

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Adam Jaffe

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

1 reference

2014

1 reference

International Journal of Pediatrics

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

2014

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

571609

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

12 June 2020

start time

1 January 2014

1 reference

April 2022 Public Data File from Crossref

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

7 April 2017

1 reference

https://api.crossref.org/works/10.1155/2014/571609

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

22 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Preventing respiratory syncytial virus infections

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Palivizumab for preterm infants. Is it worth it?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Lower respiratory tract illness and RSV prophylaxis in very premature infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Management of infections caused by respiratory syncytial virus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Immunoglobulin for preventing respiratory syncytial virus infection.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Respiratory syncytial virus infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Severe viral respiratory infections in infants with cystic fibrosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children

31 May 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Substantial variability in community respiratory syncytial virus season timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F571609

Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4274815

Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003

28 November 2018

1 reference

12 December 2020

Palivizumab efficacy in preterm infants with gestational age ≤30 weeks without bronchopulmonary dysplasia

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis

1 reference

12 December 2020

Identifiers

DOI

10.1155/2014/571609

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

PubMed publication ID

25548575

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25548575%20AND%20SRC:MED&resulttype=core&format=json